Undisclosed mbIL-15 TCR T-cell therapy / Alaunos Therap - LARVOL DELTA

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023 (GlobeNewswire) - "Optimize manufacturing process towards commercial scalability: The Company continues to execute on its multi-pronged strategy to expand manufacturing capacity and efficiency....The Company also filed an IND amendment to move from fresh to cryopreserved product and expects to begin implementing this change in the first half of 2023....Explore next generation TCR-T cell therapy approaches to deepen clinical responses: The Company is advancing its mbIL-15 TCR-T cell therapy program towards an IND filing anticipated in the second half of 2023."

Commercial • IND • Oncology • Solid Tumor

Alaunos Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) - "Today, the Company will present preclinical data for its mbIL-15 program at the ASGCT 25th Annual Meeting. The poster titled, 'Stem-cell memory TCR-T cells targeting hotspot EGFR, KRAS and p53 neoantigens generated through co-expression of membrane-bound Interleukin-15' highlights the potential of mbIL-15 to establish long-lived tumor-specific TCR-T cells. The Company intends to file an IND application for this program in the second half of 2023."

IND • Preclinical • Oncology